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NeointimaQuiescin sulfhydryl oxidase 1 (QSOX1) is a ﬂavoenzyme largely present in the extracellular milieu whose phys-
iological functions and substrates are not known. QSOX1 has been implicated in the regulation of tumor cell
survival, proliferation and migration, in addition to extracellular matrix (ECM) remodeling. However, data re-
garding other pathophysiological conditions are still lacking. Arterial injury by balloon catheter is an established
model of post-angioplasty restenosis. This technique induces neointima formation due tomigration and prolifer-
ation of vascular smooth muscle cells (VSMC), followed by ECM synthesis and remodeling. Here, we show that
QSOX1 knockdown inhibited VSMCmigration and proliferation in vitro. In contrast, QSOX1 overexpression stim-
ulated these processes. While migration could be induced by the incubation of cells with the active recombinant
QSOX1, proliferation was induced by addition of the active and also of an inactive mutant QSOX1 protein. The
proliferation induced by both recombinants was independent of intracellular hydrogen peroxide and dependent
of the MEK/ERK pathway. To recapitulate in vivo VSMC pathophysiology, balloon-induced arterial injury
was performed. The expression of QSOX1 in the neointimal layer of balloon-injured rat carotids was high and
peaked at 14 days post-injury. In vivo QSOX1 knockdown led to a signiﬁcant decrease in PCNA expression at
day 14 post-injury and a decreased intima/media area ratio at day 21 post-injury, compared with scrambled
siRNA transfection. In summary, ourﬁndings demonstrate that QSOX1 induces VSMCmigration and proliferation
in vitro and contributes to neointima thickening in balloon-injured rat carotids.
© 2015 Published by Elsevier B.V.1. Introduction
Quiescin sulfhydryl oxidase 1 (QSOX1) is a ﬂavin-linked sulfhydryl
oxidase that localizes to the ER/Golgi apparatus [1,2] or the extracellular
milieu [1,3–10]. QSOX1 exists in two isoforms that are produced by
alternative splicing [11]. The short QSOX1, the most abundantly
expressed isoform [12], is secreted [5,8,13], while the long isoform is a
transmembrane protein [14] that was recently demonstrated to be; bFGF, basic ﬁbroblast growth
matrix; ERK1/2, extracellular
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tural, Molecular e Genética,
zil.proteolytically cleaved to a soluble and secreted variant [15]. Due to
the extracellular localization of QSOX1, roles related to extracellular
matrix (ECM) remodeling or extracellular protein assembly have been
attributed to this protein [12]. Indeed, the requirement for QSOX1 activ-
ity to incorporate laminin trimer into the ECM, providing a functional
surface,was shown [16]. In addition, extracellular QSOX1has been asso-
ciated with tumor progression [17–21] due to the activation of cellular
proliferation andmatrix metalloproteinases (MMP) [20,22]. In contrast,
previous studies have demonstrated that QSOX1 negatively regulates
cell cycle progression [4,23–25]. However, despite such ﬁndings, data
regarding the physiological substrates and roles of QSOX1 remain
scarce.
Recently, a role for QSOX1 in the cardiovascular system has
emerged. It has been found in the supernatants of aortic smoothmuscle
cells (SMC) and smooth muscle progenitor cells with proteomic
approaches [9] and in the necrotic areas of atherosclerotic plaques
[26], and it has been described as a possible marker of heart failure
[27]. Additionally, protein disulﬁde isomerase (PDI), which cooperates
with QSOX1 during protein folding and isomerization [28], regulates
the activity of vascular NADPH oxidase [29], which is a key element of
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catheter induces neointima formation followed by constrictive remod-
eling, as primarily determined in experimental models of restenosis
[32,33]. It is widely accepted that medial SMC respond to injury, imme-
diately proliferating andmigrating to the intima. There, neointimal cells
continue proliferating, reaching a maximum rate between 4 and 7 days
post-injury [34]. The resulting neointima prominently appears at day
14, after which ECM remodeling takes place [35], while proliferation
and migration cease [33,36].
Because neointima thickening is mediated by cell migration, cell
proliferation and ECM synthesis/remodeling, we postulated that
QSOX1 might have a role in this process. Our ﬁndings demonstrate
that QSOX1 induces vascular smooth muscle cell (VSMC) migration
and proliferation in vitro and contributes to neointima thickening in
balloon-injured rat carotids.
2. Material and methods
2.1. VSMC culture
Aortaswere obtained frommaleWistar ratsweighing 250 g. Arteries
were dissected and rinsedwith PBS containing antibiotics and fungicide.
The media layer was then cut into 1-mm2 fragments. These explants
were plated with their luminal surfaces facing upward in a 35-mm
culture dish and coveredwith 0.5mL high glucose DMEM (Life Technol-
ogies) containing 20% fetal calf serum (Life Technologies) and 40 mg/L
Garamycin® (Schering-Plough). After migration, VSMC were detached
with trypsin and subcultured in DMEM containing 10% fetal calf
serum and antibiotics. VSMC identity was conﬁrmed by immunoﬂu-
orescence with anti-smooth muscle actin (Sigma-Aldrich). Cells in
passages 3–7 were assayed [37]. This protocol was approved by the
Research Ethics Committee (CEUA) of the Biological Sciences Building,
protocol number 412/2009.
2.2. QSOX1 knockdown and overexpression in VSMC
QSOX1-speciﬁc siRNA (targeting both QSOX1 transcripts) and
scrambled siRNA duplexes (Stealth RNAi™, Invitrogen) were designed
with Block-iT RNAi Designer. Sense sequences corresponding to the
QSOX1 and scrambled duplexes were 5′-UGGAGCCUGCCAAGCUGAAG
GAUAU-3′ and 5′-UGGCCGUCCAACGGUAAGGAGUAU-3′, respectively.
QSOX1 knockdown was achieved by transfecting VSMC with 50 nM
QSOX1 siRNA or scrambled siRNA duplexes using Oligofectamine
(Invitrogen). Cells (10–25 × 103 cells/cm2) were transfected in
OptiMEM (Life Technologies) for 4 h, after which the transfection
mediumwas replaced by complete medium, unless otherwise stated.
For QSOX1 overexpression, VSMC (106) were resuspended in 0.4 mL
OptiMEM and electroporated with 10 μg of QSOX1-pCR3.1 [5], corre-
sponding to the short secreted isoform, or empty pCR3.1 (mock) plas-
mid in a Gene Pulser XCell electroporation device (BioRad). The
electroporation settings were: 300 V, 500 μF and a resistance of inﬁnity
at exponential decay. Cells were kept at room temperature for 30 min
and then plated to recover. Twenty-four hours later, they were seeded
at a speciﬁc density for each assay [38].
2.3. Recombinant mouse QSOX1 production and activity
Recombinant wild type short isoform QSOX1 (herein referred to as
mQSOX1) was produced as previously described [39]. Mouse and rat
QSOX1 are 91% identical in their amino acid sequences, and a recent
study showed that metazoan QSOX share domain organization and
enzymatic mechanism [40], enabling the use of mouse proteins with
rat cells. The mutant inactive enzyme [41] (herein referred to as
mQSOX1C452S) was obtained by mutating the ﬁrst cysteine residue of
the second CXXC motif of the wild type construct using Megaprimer
PCR method [42]. A ﬁrst PCR round was performed to produce amegaprimer with a site-directed mutation using the forward primer
5′-CTTCTTTGGCAGTCGTGACTGTGC-3′ (nucleotide substitution
underlined) and the reverse primer 5′-ATCGTCATAGACTCTTCTTGA
AAGCTTGGG-3′ (HindIII site underlined). The second PCR round was
performed with the puriﬁed megaprimer (306 bp) as the reverse
primer and 5′-GGGGTACCTACTCGTCCTCTGAC-3′as the forward primer
(KpnI site underlined). The mutant amplicon was doubled-digested
with KpnI and HindIII, and the puriﬁed insert was cloned into the
pET32a vector (Novagen). Protein concentrations were determined
using ε456nm = 12.5 mM−1 × cm−1 [43] or Bradford assay. Dithio-
threitol oxidase activity was determined as previously described
[44]. While the wild type QSOX1 produced an average activity of
123 nmol H2O2/min/mg protein, the mutant protein was completely
inactive, asmeasured before each assay. For some experiments, LPSwas
removed from the recombinant proteins with Detoxi-Gel® Endotoxin
Removing Gel (Thermo Scientiﬁc).
2.4. Migration assays
The wound migration assay was performed as previously described
[45]. Brieﬂy, 105 cells were plated in 6-well plates. After the transfec-
tions, a P-200 pipette tip scraped the dish surface to generate a
“wound”. Cells were then cultivated in DMEM with 0.1% fetal calf
serum. After 24, 48 and 72 h, cells were gently rinsed with PBS and
photographed. Migration was calculated as migration distance. For
this purpose, the difference in the distance between the edges of a
scratch at the indicated times in relation to the distance measured at
time 0 was calculated. In some assays, mQSOX1 or mQSOX1C452S re-
combinant proteins (50 nM)were added immediately after transfection
with siRNA for the indicated times, in DMEM containing 0.1% fetal calf
serum. Cell migration was also assessed using a transwell system with
8-μmpores (Corning). VSMC (5 × 105) were seeded in the upper cham-
ber in DMEM containing 0.1% fetal calf serum. DMEM containing
20 ng/mL PDGF-BB (Peprotech) or 10% fetal calf serum was added into
the lower chamber at the indicated times to stimulate migration. After
6 h, cells on the upper surfacewere removed by gentlewipingwith a cot-
ton swab, while migrating cells were counted in a hemocytometer [46].
2.5. Proliferation assay
Cells (5 × 104) were plated in 96-well microplates (TPP). Twenty-
four, 48 and 72 h after transfection with siRNA or plasmids, cells were
collected and analyzed by crystal violet staining as described [47].
In some assays, mQSOX1 or mQSOX1C452S recombinant proteins
(5 or 50 nM), in the absence or presence of polyethyleneglycol (PEG)-
catalase (200 U/mL, Sigma-Aldrich) [48] or MEK1/2 inhibitor U0126
(10 μM, Calbiochem), were added immediately after transfections
with siRNA in the culture medium containing 10 or 0.1% serum, for
the indicated times. Serum starvation (0.1% fetal calf serum for 24 h)
was performed in some experiments, as indicated in the legends.
2.6. Cell viability
Cell viability was assessed with an MTT assay, as previously
described [47].
2.7. Quantitative PCR
Total RNAwas extracted from 105 VSMC using the Invitrap Spin Cell
RNA Mini Kit (Invitek) according to the manufacturer's protocol. Com-
plementary DNAwas synthesized from 50 ng total RNA, after treatment
of RNAwith DNAse. Relative mRNA expression levels were determined
using hypoxanthine-guanine phosphoribosyltransferase (HPRT) as a
housekeeping gene and the 2−ΔΔCTmethod. Reactions were performed
in a Rotor-Gene 6000 thermocycler (Corbett) using a SYBR Green
PCR Kit (Qiagen). The QSOX1 primers (which detected both QSOX1
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5′-GAAGTGGAAGAGGACCCACA-3′. The HPRT primers were: forward
5′-CAGGCCAGACTTTGTTGGAT-3′ and reverse 5′-TCCACTTTCGCTGATG
ACAC-3′. All primers were validated with the 2−ΔΔCT method [49].
2.8. SDS-PAGE and immunoblotting
Cells (5 × 105) were plated in 100-mm dishes (TPP). At 24, 48 and
72 h after transfection, cells were lysed (10 mM Tris–HCl pH 7.4 con-
taining 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1%
deoxycholate, a protease inhibitor cocktail (Roche) and phosphatase
inhibitors for 15 min at 4 °C). After centrifugation (10,000 × g, 10 min),
supernatantswere collected, and the protein contentswere determined
with Bradford reagent (BioRad). Proteins were separated on a 10% SDS-
PAGE gel and electroblotted on to a nitrocellulose membrane.
Membranes were blocked with 5% skim milk. The antibodies used
were rabbit polyclonal anti-PCNA (1:200, Dako), mouse monoclonal
anti β-actin (1:1000, Sigma), mouse anti-phospho ERK1/2 (1:1000,
Santa Cruz), mouse monoclonal anti-calponin (1:1000, Sigma), rabbit
anti-ERK1/2 (1:1000, Cell Signaling), anti-rabbit IgG coupled to HRP
(1:1000, Sigma-Aldrich) and anti-mouse IgG coupled to HRP (1:5000,
Sigma-Aldrich). Reactions were developed with a West Pico or Femto
chemiluminescence kit (Pierce) and bands were detected on autoradi-
ography ﬁlms (Thermo).
2.9. Determination of quiescence by ﬂuorescence analyses
Cells (104) were harvested, washed twice with PBS and stained
with 5 μg/mL Hoechst 33342 solution for 45 min at 37 °C and thenFig. 1. Effects of QSOX1 knockdown and overexpression on VSMC. QSOX1 mRNA expression
(B) VSMC were evaluated at 24, 48 and 72 h post-transfection. mRNA levels were quantiﬁed b
in scrambled andQSOX1 siRNA-transfected (C) or inmock and pCR3.1QSOX1-transfected (D) c
medium. The results correspond to the mean ± SD of 3 (A, B) or 4 (C, D) independent experimwith 100 μg/mL pyronin Y for 10 min [50,51]. Fluorescence (λexc =
350 nm, λem= 461 nm and λexc = 488 nm, λem= 550 nm for Hoechst
33342 and pyronin Y, respectively) was measured in a microplate
reader (Tecan Inﬁnity), and the relative RNA quantity was calculated
with the pyronin Y/Hoechst 33342 ﬂuorescence ratio.
2.10. Brefeldin A assay
Cells (5 × 105) were plated in 100-mm dishes (TPP), transfected
with siRNA duplexes and treated with 2.5 μg/mL brefeldin A (BFA) for
24, 48 and 72 h [52]. Cells were washed and analyzed by crystal violet
assay.
2.11. Balloon injury in rat carotid artery
Male Wistar rats weighing between 250 and 300 g were obtained
from the facility at the Universidade Federal do Paraná (UFPR). Animals
were anesthetized with an intraperitoneal injection of 100 mg/kg keta-
mine hydrochloride (Syntec) and 5 mg/kg xylazine hydrochloride
(Syntec). Endothelial denudation and intimal lesion of the left carotid
artery were performed with a balloon embolectomy catheter (2F
Fogarty, Edwards Life Sciences) as previously described [53]. Brieﬂy,
the catheter was inserted through the external carotid artery to the
common carotid artery, inﬂatedwith 0.2mL saline anddrawnwith a ro-
tarymotion. After deﬂation in the common carotid, it was removed. This
procedurewas performed three times. Some animalswere anesthetized
and underwent the procedure without the use of the balloon catheter
(sham-operated). Following balloon angioplasty, animals were kept
warm, and 0.1mg/kg scopolamine butylbromide plus 5mg/kg dipyronein scrambled or QSOX1 siRNA-transfected (A) and in mock or pCR3.1QSOX1-transfected
y quantitative PCR using the 2−ΔΔCt method. Cell viability was assessed by an MTT assay
ells at 24, 48 and 72 h after transfection. In all experiments, cells were cultured in complete
ents. *p b 0.05.
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by the Research Ethics Committee (CEUA) of the Biological Sciences
Building, protocol number 412/2009.
2.12. siRNA in vivo transfection
A 10 μg aliquot of siRNA duplex (sequences above) was dissolved in
100 μL of a 30% (m/v) pluronic gel (Sigma-Aldrich) solution and
perivascularly delivered into the rat carotid artery immediately after
injury [54]. The transfection controls were performed with 10 μg of a
control siRNA labeled with TyE (IDT) or 10 μg of pEGFP-C1 (Clontech).
2.13. Immunohistochemistry (IHC) and histochemistry
Sham-operated, injured and injured/transfected carotids, at 7, 14
and 21 days after balloon catheter injury, as well as carotids from
control (uninjured) rats were collected. Next, 5-μm-thick sections
of each specimen were subjected to immunohistochemistry at the
same time as previously described [39] with the following polyclonal
antibodies: anti-QSOX1 [8], anti-GFP (a donation of Dr. Stenio Perdigão,
ICC, Curitiba, Brazil) and anti-PCNA (Santa Cruz Biotechnology).
Immunoreactions were developed with a peroxidase mouse and rabbit
kit (Diagnostic BioSystems) using 3,3′-diaminobenzidine (DAB) as a
chromogen (Diagnostic BioSystems). QSOX1 expression was quantiﬁed
by densitometry in 6 random ﬁelds of the same section per animal using
Image J software. For histochemistry assays, tissue sectionswere stained
with Weigert Van Gieson. Images were acquired using an Axio ImagerFig. 2. Effects of QSOX1 knockdown and overexpression in VSMC migration. Cell migration w
transfected (A, C) and in mock and pCR3.1QSOX1-transfected (B, D) cells at 24, 48 and 72 h a
edges of a scratch at the indicated times in relation to the distance measured at time 0. In th
calf serum or by 20 ng/mL PDGF. During the migration periods, cells were cultured in
(C, D) independent experiments. *p b 0.05.Z.2 slide scanner microscope (Zeiss, Germany) controlled by Metafer
4-VSlide software [55,56].
2.14. Statistical analysis
Results are shown as the mean ± S.D. The exact n (number of
independent experiments with cells or number of rats) is described in
each ﬁgure legend. Statistical analyses were performed with ANOVA
with Tukey post hoc test, using GraphPad Prism 5 or 6 softwares. For
all analyses, p b 0.05 was considered statistically signiﬁcant.
3. Results
The role of QSOX1 in VSMC proliferation and migration was studied
in primary cultures of rat aortic SMC transfected with QSOX1 siRNA or
with the pCR3.1QSOX1 plasmid. The differential QSOX1 expression
was demonstrated by RT-qPCR. By comparing QSOX1mRNA expression
with corresponding controls, knockdown of approximately 50% was
achieved 24 h after siRNA transfection; the knockdown degree slowly
decreased through 48 and 72 h (Fig. 1A). An overexpression of 280%
was achieved after 24 h, decreasing to 150% after 48 h (Fig. 1B). We
then testedwhether QSOX1knockdown or overexpressionwould inter-
fere with cell viability, asmeasured bymitochondrial metabolism.With
the exception of the time point 72 h after pCR3.1QSOX1 plasmid trans-
fection, compared with the mock control, no signiﬁcant alteration was
observed (Fig. 1C, D). Overall, this result indicates that modulation of
QSOX1 expression is not associated with cell death in VSMC.as assessed by scratch (A, B) and transwell (C, D) assays in scrambled and QSOX1 siRNA-
fter transfection. Migration was calculated as the difference in the distance between the
e transwell assay, migration was calculated as the number of cells attracted by 10% fetal
0.1% fetal calf serum. Data shown correspond to the mean ± SD of 4 (A, B) or 3
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Migration was analyzed with the scratch method and with the
transwell assay. QSOX1 siRNA-transfected VSMC exhibited a decreased
migration rate compared with scrambled siRNA-transfected cells as
determined in the scratch assay, for all times analyzed (Fig. 2A). Accord-
ingly, QSOX1 overexpression led to an increased migration rate
compared with the mock control (Fig. 2B). These overexpression data
reinforce the idea that siRNA effects do not result from off-target effects
because they are complementary to the knockdown results. The
hypothesis that we were measuring cell proliferation instead of cell
migration was excluded, as VSMC did not proliferate when cultivated
with 0.1% fetal calf serum for 72 h as measured in the crystal violet
assay (data not shown). Migration through transwells conﬁrmed
the scratch results. Here, chemotaxis was performed with 10% fetal
serum or 20 ng/mL PDGF, a classical chemoattractant agent for VSMC
(Fig. 2C, D). These results show that QSOX1 has a pro-migratory effect
on VSMC.
The most abundant isoform of QSOX1, the short isoform, is reported
to be secreted into the extracellularmedium [5,8,13]. In addition, the pro-
teolytic cleavage of the long isoform, which produces a secreted active
version of QSOX1, was recently reported [15]. Thus, we asked whether
the pro-migrative effect of QSOX1 was due to the secreted isoform,
implying an extracellular role. To this end, we incubated scrambled
or QSOX1 siRNA-transfected cells with mQSOX1 or mQSOX1C452S
(Fig. 3). Fifty nanomolar mQSOX1 induced migration of VSMC in all con-
ditions compared with non-stimulated cells, i.e., VSMC cultivated in the
absence of mQSOX1. In contrast, the recombinant inactive enzyme
mQSOX1C452S did not induce migration, and even inhibited the migra-
tion at 48 h (Fig. 3). This response proﬁle to the recombinant proteins
was essentially the same in QSOX1 siRNA-transfected or scrambled
siRNA-transfected cells. However, QSOX1 knockdown led to signiﬁcant
decreased migration distances, as observed at 48 and 72 h. Efﬁciency
analysis of both recombinants in promoting cell migration showed that
cells migrated more when incubated with the wild type than with theFig. 3. Effect of exogenous extracellular recombinantQSOX1 inVSMCmigration. Scrambled orQ
the inactive recombinantmQSOX1C452S orwere left untreated. After 24, 48 or 72h of treatmen
the absence or presence of the recombinant proteins, in 0.1% fetal calf serum. Data shown corrmutant enzyme (Fig. 3). Taken together, these ﬁndings show that extra-
cellular QSOX1 induces VSMC migration and that this process is depen-
dent on the sulfhydryl oxidase activity of the enzyme. This extracellular
activity is probably derived from a combination of both the recombinant
QSOX1 and the endogenous QSOX1.
3.2. Extracellular QSOX1 has pro-proliferative properties in VSMC
Proliferation was assessed with crystal violet staining. QSOX1 siRNA
treatment induced a signiﬁcant decrease in cell proliferation compared
with the scrambled control, after 48 and 72 h (Fig. 4A). Consistent with
this observation, QSOX1 overexpression produced signiﬁcant increases
in the proliferation of pCR3.1QSOX1-transfected cells (Fig. 4B). Addi-
tionally, QSOX1 expression paralleled the expression of PCNA, a marker
of cell proliferation (Fig. 4C, D). Previous reports indicated that the
expression of QSOX1was associatedwith cellular quiescence, but recent
studies have shown that QSOX1 knockdown inhibits both proliferation
and migration of breast [20] and pancreas [22] tumor cells. Because
quiescent cells (in G0 state) have less cellular RNA than cycling cells
[50], we determined the relative amount of cellular RNA in the cells.
The results indicated that the amount of RNA was lower when QSOX1
expression was inhibited and higher when QSOX1 was overexpressed
(Fig. 4E, F). These data indicate that QSOX1 expression is not associated
with the G0 state in VSMC. Finally, because of the balance between the
proliferative/secreting and quiescent/contractile states of VSMC, we
analyzed how QSOX1 expression would affect calponin expression, a
marker of VSMC contractile phenotype [57]. The results demonstrated
that calponin expression is inversely proportional to QSOX1 expression
(Fig. 4C, D), conﬁrming the association between high QSOX1 expression
and decreased contractile phenotype.
To investigatewhether the proliferative effectwas due to extracellular
QSOX1, we incubated QSOX1 siRNA-transfected VSMC with mQSOX1.
While 5 nMmQSOX1 had no effect on QSOX1 siRNA-transfected cells at
any time point, 50 nM signiﬁcantly increased proliferation of QSOX1
knockdown cells at 24, 48 and 72 h after the treatment, compared withSOX1 siRNA-transfected cellswere scratched and treatedwith 50nMwild typemQSOX1 or
t, themigrated distancewasmeasured. During themigration period, cells were cultured, in
espond to the mean ± SD of 4 independent experiments. *p b 0.05.
Fig. 4. Effect of QSOX1 knockdown and overexpression in proliferative events in VSMC. Proliferation was assessed by crystal violet assay (A, B), PCNA and calponin expressions by immu-
noblotting (C, D) and relative RNA content by pyronin Y (PY)/Hoechst 33342 ﬂuorescence ratios (E, F) in scrambled and QSOX1 siRNA-transfected (A, C, E) or inmock and pCR3.1QSOX1-
transfected (B, D, F) cells cultivated in complete medium for the indicated times after transfection. The results correspond to the mean ± SD of 4 independent experiments, whereas the
immunoblotting data are representative blots of 3 independent assays. *p b 0.05.
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concentration-dependentmitogenic stimulation (Fig. 5). An identical pro-
ﬁle was obtained with scrambled siRNA-transfected VSMC. These results
indicate that extracellular QSOX1 induces proliferation. When VSMC
were treated with brefeldin A, a drug that blocks protein secretion by
disrupting ER-Golgi trafﬁc, proliferation was inhibited as measured with
the crystal violet assay (data not shown). Although brefeldin A hasmulti-
ple targets and even induces cell growth arrest, thismay be a result of the
blockage of QSOX1 secretion. To investigate whether this extracellular
trigger of proliferation by QSOX1 was dependent on the sulfhydryl
oxidase activity of the extracellular protein, we incubated scrambled
siRNA- and QSOX1 siRNA-transfected VSMC with mQSOX1C452S. The
results obtained were very similar to those obtained with mQSOX1. The
mutant protein stimulated the proliferation of VSMC, with or without
QSOX1 knockdown, signiﬁcantly at 50 nM (Fig. 5). In contrast with the
5 nMmQSOX1, 5 nMmQSOX1C452S was able to promote the prolifera-
tion of both scrambled siRNA- and QSOX1 siRNA-transfected cells at
24 h, suggesting a slightly higher efﬁciency of 5 nMmutant QSOX1. How-
ever, in QSOX1 siRNA-transfected cells, 50 nMwild type was more effec-
tive than themutant enzyme at 24 and 48 h (Fig. 5). Therefore, under our
experimental conditions, the proliferative effect of QSOX1 in VSMC istriggered by extracellular QSOX1 and, overall, does not depend on its sulf-
hydryl oxidase activity. To exclude a possible role of LPS contamination,
this assay was performed with LPS-free recombinant proteins. The incu-
bation of non-transfected VSMCwith 5 and 50 nMwild type andmutant
QSOX1 for 24, 48 and 72 h provided the same results as those shown in
Fig. 5 (data not shown), demonstrating that the enhanced proliferative
effect was not due to LPS. Also, a 24 h-starvation with 0.1% fetal calf
serum, followed by incubation with the recombinant proteins in com-
plete medium provided identical results as those from non-starved cells
(data not shown), indicating that cellular synchronization does not affect
VSMC proliferation induced by QSOX1. Tominimize the effects of growth
factors from the bovine serum,we starved cells (24h-starvationwith 0.1%
fetal calf serum) and then incubated with recombinant QSOX1 in the
same starvation medium. The results showed that even under low
serum, incubation of VSMC with QSOX1 and PDGF led to increased cell
proliferation, compared with the non-stimulated control cells (Suppl.
Fig. 1), and that both the wild type and the mutant QSOX1 induced
cell proliferation, compared with the control cells, in a time- and dose-
dependent way (Suppl. Fig. 1). Moreover, under such low serum condi-
tion, the mutant QSOX1 showed an enhanced effect compared with the
wild type.
Fig. 5. Effect of exogenous extracellular recombinant QSOX1 in VSMC proliferation. Scrambled or QSOX1 siRNA-transfected cells were treated with 5 or 50 nMwild type mQSOX1 or the
inactive recombinant QSOX1mQSOX1C452S orwere left untreated, in DMEM containing 10% fetal calf serum. After 24, 48 or 72 h of treatment, proliferationwas assessed by crystal violet
assay. Data shown correspond to the mean ± SD of 3 independent experiments. *p b 0.05.
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proliferative effect of exogenous QSOX1, we treated the VSMC with
wild type or mutant QSOX1, in medium containing 0.1% fetal serum
and PEG-catalase for 48 h, andmeasured cell proliferation (Fig. 6). Addi-
tion of PEG-catalase to the cells inhibited the proliferation induced by
PDGF (Fig. 6). However, it did not affect the proliferation induced by
mQSOX1 and mQSOX1C452S, indicating that the mitogenic signaling
induced by extracellularQSOX1 does not dependon intracellular hydro-
gen peroxide.Fig. 6. Effect of PEG-catalase in VSMC proliferation induced by recombinant QSOX1. VSMCwere
QSOX1 mQSOX1C452S or were left untreated, in DMEM containing 0.1% fetal calf serum, in th
crystal violet assay. Data shown correspond to the mean ± SD of at 4 independent experimen3.3. MEK1/2–ERK1/2 pathway is involved in QSOX1-induced proliferation
of VSMC
ERK1/2 are usually activated by mitogens. To assess whether this
pathway was also activated by recombinant QSOX1, we performed a
proliferation assay in the absence or in the presence of U0126, an inhib-
itor of MEK1/2, the upstream ERK1/2 kinase. Inhibition of ERK1/2 acti-
vation by U0126 inhibited cell proliferation promoted by PDGF and by
50 nM mQSOX1 and mQSOX1C452S proteins (Fig. 7A). In agreement,incubatedwith 20 ng/mL PDGF-BB, 50 nMwild typemQSOX1 or the inactive recombinant
e presence or absence of 200 U/mL PEG-catalase. After 48 h, proliferation was assessed by
ts. *p b 0.05; ns, non-signiﬁcant.
Fig. 7.Effect ofMEK1/2 inhibitor U0126 inVSMCproliferation and in ERK1/2 phosphorylation. (A)VSMCwere serum-starved (0.1%) for 24h and incubatedwith 20ng/mLPDGF-BB, 50 nM
wild typemQSOX1 or the inactive recombinant QSOX1mQSOX1C452S or were left untreated, in DMEM containing 0.1% fetal calf serum, in the presence or absence of 10 μMU0126. After
48 h, proliferation was assessed by crystal violet assay. Data shown correspond to the mean ± SD of 3 independent experiments. Statistically signiﬁcant differences (*p b 0.05) are indi-
cated. (B) VSMCwere incubated with 50 nMwild type mQSOX1 or the inactive recombinant QSOX1mQSOX1C452S or were left untreated, in DMEM containing 0.1% fetal calf serum, for
the indicated times, in the absence or presence of 10 μM U0126. Total protein extracts (50 μg) were electrophoresed and immunoblotted with anti-phospho ERK1/2 and anti-ERK1/2
antibodies.
1341B.E. Borges et al. / Biochimica et Biophysica Acta 1852 (2015) 1334–1346addition of both 50 nM recombinant QSOX1 triggers a rapid ERK1/2
phosphorylation, which is completely abolished by the presence
of U0126 (Fig. 7B). Thus, these ﬁndings show that both wild type
and the inactive QSOX1 induce VSMC proliferation in a MEK1/2–
ERK1/2-dependent pathway.3.4. Contribution of QSOX1 to neointimal growth in balloon-injured
rat carotid
To investigate the clinical implications of QSOX1 in VSMC,
we ﬁrst analyzed if QSOX1 was expressed by healthy arteries.
Fig. 9. QSOX1 expression in neointima after in vivo siRNA transfection in rat carotids.
Immediately after balloon catheter injury, 10 μg of scrambled (n = 15 rats/time point)
or QSOX1 (n = 15 rats/time point) siRNA were delivered to the injured artery. At days
7, 14 and 21 after the injury, carotid sections were immunostained with anti-QSOX1,
and QSOX1 expression was quantiﬁed by densitometry in 6 random ﬁelds/rat. The values
represent the mean ± SD. *p b 0.05.
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carotids are relatively low in the media layer (Supp. Fig. 2). As a patho-
logical condition, we employed arterial injury by balloon catheter, a
more complex model of vascular disease. Injury by balloon catheter in
rat carotids led to intimal hyperplasia, with a prominent neointimal
layer observed 14 days after the lesion (Supp. Fig. 3). We then analyzed
QSOX1 expression. The results indicated that the medial layer
expressed a constant low level of QSOX1 through 21 days post-injury.
In the neointimal layer, QSOX1 expression increased until 14 days
after lesion, when it is maximal, after which it decreases (Fig. 8). There-
fore, in contrast with QSOX1 present in media, QSOX1 in the neointima
might play a role in neointimal growth. Thus, we next asked whether
decreased QSOX1 expression would interfere with the development
of the neointima. We employed pluronic gel to perform an in vivo
transfection of siRNA and knockdown QSOX1 expression in the injured
carotid. The efﬁciency of this method was validated by analyzing the
transfection of a ﬂuorophore-labeled siRNA and of GFP expression in
the rat carotid 48 h after transfection of a plasmid bearing the GFP
gene. The results indicated that siRNA-TyE (data not shown) and the
perivascularly-delivered plasmid reached the medial cells (Supp.
Fig. 4). Transfection of siRNA speciﬁc for the QSOX1 gene immediately
after the balloon injury induced decreased QSOX1 protein expression
by approximately 50% at days 14 and 21 compared with the scrambled
siRNA (Fig. 9). Thus, pluronic gel-mediated siRNA transfection provided
sustained QSOX1 knockdown in vivo, as previously described [54].
Finally, analysis of the neointima/media area ratio demonstrated that
this ratio was signiﬁcantly decreased by ~30% after QSOX1 knockdown
in injured arteries at day 21 compared with the scrambled control
(Fig. 10). As neointima growth is a result of VSMC migration, prolifera-
tion andmatrix secretion,we assessedwhether decreased expression of
QSOX1 inhibited cell proliferation. Indeed, the neointimal expression of
PCNAwas highly inhibited (70% compared with the scrambled control)Fig. 8. QSOX1 expression and quantiﬁcation in rat carotids after balloon catheter injury. (A) Re
immunostained with anti-QSOX1 at 7, 14 and 21 days after the injury. The carotid sections we
(B) and media (C) layers by densitometry in 6 random ﬁelds/rat. The values represent the meain the nuclei of QSOX1 knockdown carotids at day 14. Interestingly,
at this time, PCNA expressionwasmaximal in the scrambled control ar-
teries, which indicated that scrambled siRNA-transfected neointimal
cells were actively dividing on day 14 (Fig. 11). Collectively, these
data demonstrate that QSOX1 contributes to neointima thickening
after balloon injury in rat carotids.presentative photomicrographs of catheter-injured (15 rats/ time point) carotid sections
re photographed at 400× magniﬁcation. QSOX1 expression was determined in neointima
n ± SD. *p b 0.05.
Fig. 10. Effect of QSOX1 knockdown on the neointima/media area ratio. (A) Representative photomicrographs of scrambled (n = 15 rats/time point) or QSOX1 (n= 15 rats/time point)
siRNA-transfected injured carotid sections, stainedwithWeigert Van Gieson solution at 7, 14 and 21 days after lesion. The carotid sectionswere photographed at 400 xmagniﬁcation. Line
indicates tunica media while dot indicates tunica intima or neointima. (B) Areas were measured with Image J software, and neointima/media area ratios were calculated. The values
represent the mean ± SD. *p b 0.05.
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To investigate the role of QSOX1 in VSMC, we ﬁrst modulated its ex-
pression by QSOX1 siRNA or QSOX1 plasmid. Our in vitro results clearly
demonstrate that QSOX1 knockdown inhibits VSMC migration, while
QSOX1 overexpression enhances it. These results are in agreement
with recent ﬁndings [20,22] demonstrating that QSOX1 knockdown in-
hibits tumor cell invasion. Migration is one step of the invasion process,
and those authors proposed that QSOX1 post-translationally activates
MMP-2 and MMP-9. Given that the pro-migratory function depends
on sulfhydryl oxidase activity, QSOX1 may introduce disulﬁde bonds
in extracellular substrates such as ECM proteins or exofacial thiol pro-
teins, triggering migration. The importance of the ECM in cell adhesion
and migration is well known, and ECM dysfunction underlies vascular
pathologies [35,58–60]. Indeed, while our work was in progress, the
Fass group demonstrated that QSOX1 knockdown in WI38 ﬁbroblasts
led to a decreased number of cells in the monolayer compared with
scrambled control ﬁbroblasts [16]. The addition of active recombinant
QSOX1 prevented this effect, while the inactive mutant did not. The
interpretation of these results was that QSOX1 knockdown impairs
the adhesive capacity of the ﬁbroblasts by limiting the incorporation
of laminin into the ECM, a process supported by extracellular QSOX1
activity [16]. Exofacial thiol proteins may also be targets of QSOX1, as
some of these contain redox-regulated cysteine residues [61–64],
which can regulate cell functions [62,63]. Finally, hydrogen peroxide,the product of QSOX1 catalysis, could also activate intracellular redox
signaling, mimicking that triggered by PDGF [65], leading to VSMC
migration (for a review, see [66]).
Additionally, here we also showed that QSOX1 has a pro-
proliferative role in VSMC. While QSOX1 knockdown leads to a de-
creased number of cells compared with the scrambled control, QSOX1
overexpression increases the amount of VSMC. One could interpret
this ﬁnding as indicating that QSOX1 is pro-survival, as has already
been described for PC12 cells [67] or similar to the small sulfhydryl ox-
idase ALR in hepatocytes [68]. However, compared with the scrambled
control, QSOX1 knockdown also promoted decreased PCNA expression
and decreased relative RNA content in VSMC, indicating that suppres-
sion of QSOX1 expression results in less cell cycle activity. In agreement
with this, QSOX1 overexpression led to increased PCNA expression and
increased RNA content. Collectively, these data support the concept that
QSOX1 is mitogenic, stimulating the entrance of VSMC into the cell
cycle. QSOX1 upregulation has long been associated with a reversible
quiescent state in several cell lines, such as WI38 ﬁbroblasts [4,23],
endothelial cells [4,25] and endometrial cells [24]. However, more
recent data have shown that QSOX1 expression may also be positively
correlated with prostate [17,19], pancreas [18] and breast [20,21]
tumor progression, likely because expression of QSOX1 promotes
tumor cell proliferation and invasion [20,22], which is in agreement
with our ﬁndings. The fact that proliferation did not appear to depend
on sulfhydryl oxidase activity suggests that QSOX1 could be acting as
Fig. 11. Effect of QSOX1 knockdown on PCNA expression in the neointima. (A) Representative photomicrographs of scrambled (n=12 rats/time point) or QSOX1 (n=12 rats/time point)
siRNA-transfected injured carotid sections immunostained with anti-PCNA at 7, 14 and 21 days after the injury. The carotid sections were photographed at 400× magniﬁcation. Line
indicates tunica media, while dot indicates tunica intima or neointima. (B) PCNA expression was measured by densitometry in 6 random ﬁelds/rat with Image J software. The values
represent the mean ± SD. *p b 0.05.
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mitogenic signaling [69]. In this context, the fact that, under low
serum, the mutant enzyme has an enhanced proliferative effect com-
pared with the wild type may indicate that thiol oxidation (in the
ECM or at cell surface) may slightly balance the proliferative effect pro-
moted by the structural conformation of QSOX1. Although the detailed
mechanismunderlyingQSOX1-inducedmitogenesis remains unknown,
our data demonstrate that it does not depend of intracellular hydrogen
peroxide, in contrast with the proliferation induced by PDGF [69], and
that activation ofMEK/ERK pathway is involved. Thus, QSOX1 promotes
VSMC proliferation and migration by distinct and independent mecha-
nisms, as reported for in vivo [70]. Regarding the relative roles of each
QSOX1 isoform, since our siRNA and qPCR primers recognize both
the long and the short versions of the oxidase, we cannot discriminate
the contribution of each one. However, because we overexpressed the
short QSOX1 andwe employed the short QSOX1 in recombinant assays,
the pro-proliferative and pro-migratory roles of this protein become
clear, although the effects of the long isoform cannot be excluded.
Our in vivo results demonstrate that QSOX1 participates in neointi-
mal formation, as QSOX1 knockdown promotes a signiﬁcant decrease
in neointima thickness at day 21. Neointimal growth is a complex
process, requiring the activity of countless molecules [33]. Therefore, it
is not unexpected that the knockdown of a single protein does not
completely block such a process but rather impairs it. Of note, sinceQSOX1 knockdown is associatedwith tumor endothelial cells' prolifera-
tion [4,22] andQSOX1 effects are associatedwith lungﬁbroblasts' quies-
cence [24], it is possible that the overall effects of perivascular QSOX1
knockdown also involves, in a more complex way, additional effects
on the vasculature, such as endothelialization and adventitial remodel-
ing. Our data also showed that QSOX1 knockdown led to decreased ex-
pression of PCNA in neointimal cells at day 14 comparedwith scrambled
siRNA-transfected injured artery, indicating that QSOX1 controls cell
proliferation, either directly or indirectly. Because QSOX1 expression
within the media layer was not altered by 21 days after lesion forma-
tion, the initial migration and/or proliferation of medial VSMC to the in-
tima is most likely induced by factors other than QSOX1, such as PDGF,
bFGF, other growth factors or other cytokines. Indeed, it was previously
shown that PDGF stimulates SMCproliferation andmigration during the
ﬁrst 7 days after endothelial denudation [71]. Our results revealed that
cells forming the early neointimal layer express QSOX1 at day 7, and
this expression peaks at day 14. Therefore, we suggest that between 7
and 14 days post-injury, neointimal-secreted QSOX1 induces medial
cell migration to the intima and proliferation and then activates neoin-
timal cell proliferation in an autocrine manner, as described for ALR in
hepatocytes [72]. Thus, the role of QSOX1 in neointimal growth is not
immediate; rather, it is associated with its expression by neointimal
cells. Suppression of QSOX1 expression by these cells inhibits VSMC
migration and proliferation primarily at days 7 and 14, leading to an
1345B.E. Borges et al. / Biochimica et Biophysica Acta 1852 (2015) 1334–1346observable and signiﬁcantly reduced intima/media area ratio only at
day 21. It is important to note that although smooth muscle cells are
considered to be the main component of neointima, other cell types
are also reported to be present, such as ﬁbroblasts and bone marrow-
derived cells [73], which might also contribute to QSOX1 expression.
In conclusion, our in vitro and in vivo results provide clear evidences
that QSOX1 positively regulates proliferation and migration of VSMC,
thus contributing to neointima growth induced by balloon injury.
Importantly, the relatively modest extent of the effects promoted by
QSOX1 knockdown implies that QSOX1 does not play solitary roles
in proliferation and migration but rather collaborates with other
molecules in such processes. Therefore, our data indicate novel roles
for QSOX1 in a disease-related model of vascular repair after injury.
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